NEW YORK (GenomeWeb) – Lonza announced today that it has acquired HansaBioMed Life Sciences, an Estonian exosome research tool developer, and made an investment in Exosomics, an Italian molecular diagnostics startup.

Financial and other terms of the agreements were not discussed.

The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.